| 1 |
Development of YH32367, a novel HER2/4-1BB bispecific antibody for the treatment of HER2 expressing solid tumors |
| Antibody |
1st indication: HER2-positive Biliary Tract Cancer Other Indications: HER2-expressing solid tumors |
HER2/4-1BB |
Phase 2 |
YUHAN |
RS-2025-25454580 |
|
| 2 |
Phase 2 Clinical Trial of Poseltinib for the Treatment of Relapsed/ Refractory Primary Central Nervous System Lymphoma |
| Small molecules |
PCNSL |
BTK, TEC |
Phase 2 |
NOBO Medicine, Inc. |
RS-2025-02212979 |
|
| 3 |
Phase 2 clinical study of innovative CD19-targeted CAR-T |
| Cell therapies |
Cancer |
CD19 |
Phase 2 |
Ab Clon Inc. |
RS-2024-00332815 |
|
| 4 |
Global phase 2 studies of precision medicine based c.MET inhibitor ABN401 |
| Small molecules |
Solid tumor, NSCLC |
c.MET |
Phase 2 |
Abion Inc. |
RS-2023-00284103 |
|
| 5 |
Development of a new class of PSMA target radiopharmaceuticals for prostate cancer |
| RPT |
Castration-resistant prostate cancer |
PSMA |
Phase 2 |
FutureChem Co., Ltd. |
RS-2023-00218051 |
|
| 6 |
Development of Novel Radiopharmaceutical for Prostate Specific Membrane Antigen Targeted Therapy |
| RPT |
Prostate cancer |
PSMA |
Phase 2 |
CellBion Co., Ltd. |
HN21C0626 |
|